Scientists harness exosomes for delivery

Exosomes are tiny packets that cells already use to send molecules to each other. That is why drug developers keep circling back to them. In theory, they can carry RNA, proteins, or small-molecule drugs through the body in a way synthetic particles often struggle to match. The news here is not one single miracle cure. It is that a cluster of recent papers and reviews in 2026 made the same point from different angles — exosomes are starting to look less like a neat lab trick and more like a real delivery platform. ### What is an exosome, exactly? An exosome is a nanoscale vesicle — basically a membrane bubble, usually around 30 to 150 nanometers wide — that cells naturally release. Those bubbles already carry proteins, lipids, and genetic material between cells, so researchers are trying to repurpose them as delivery vehicles instead of building everything from scratch. That natural origin is and sometimes better at slipping across biological barriers than standard nanoparticles. ### Why are people excited about delivery? Because delivery is usually the part that breaks the drug. Lots of therapies work in a dish but fail in a body because they cannot survive circulation, get into the right tissue, or cross barriers like the blood-brain barrier or the blood-retinal barrier. Exosomes offer a possible workaround. Researchers can load them with cargo and, in some specific cell types. ### What actually changed this year? The field got a stronger pile of concrete examples. A May 2026 review in Molecular Medicine framed exosomes as next-generation targeted carriers across cancer, neurology, and regenerative medicine. A February 2026 Nature Reviews Bioengineering piece did the more sobering version — yes, extracellular vesicles look promising, but the real bottlenecks are now yield, because it means the conversation has moved from “could this ever work?” to “which parts are ready, and which still break at scale?” ### What is the best recent example? The cleanest recent demo came in Science Advances last month. A team built eye drops from semen-derived exosomes, added folic acid targeting, and loaded them with a nanozyme system aimed at retinoblastoma. In mice, those exosomes crossed ocular barriers, reached the posterior eye, inhibited tumor growth, and preserved retinal function. That is a success. ### Is this only about the eye? No — the same logic is showing up elsewhere. A 2024 Science Translational Medicine study used engineered exosomes to deliver CRISPR-related protein machinery into Alzheimer’s mouse models and reported reduced Bace1 expression, less amyloid pathology, and improved memory readouts. Another 2026 Nature Communications paper described fused exosomes that preferentially target bowel disease. Different disease, same thesis: the carrier is becoming part of the therapy. ### So why is this still early? Because making exosomes useful is not the same as making them manufacturable. You need enough vesicles, with consistent contents, clean purification, predictable biodistribution, and stable storage. You also need to know where they go when they miss. Native exosomes are messy. Engineered exosomes are better targeted, but they add complexity fast. Are they already approved? Not as mainstream human drugs in the US. Clinical work exists — including trials of MSC-derived exosomes carrying KRASG12D siRNA for metastatic pancreatic cancer and other exploratory programs — but the field is still mostly in early-stage translation rather than broad clinical use. That gap between scientific momentum and regulatory reality is the main thing to keep straight. ### What is the bottom line? Exosomes are starting to earn serious attention because they may solve the ugliest part of medicine delivery — getting the payload to the right place intact. But the real story in 2026 is not that the problem is solved. It is that researchers now have enough convincing animal and platform data